Home Angiogenesis VDA

VDA

Cancer cells can survive and grow becasue they have tumour vasculature to get blood, nutrients and oxygen. As it is, the tumour vasculature is an attractive target for cancer therapy. Now researchers develop 2 kind of drugs targeting angiogenesis which are VTAs (Vascular targeting agents) and VDAs (Vascular disrupting agents). VTAs(Vascular targeting agents) can prevent new blood vessels from forming with on functions on blood vessels that already feed existing tumors.In contrast, VDAs (Vascular disrupting agents) lead to the vascular structure of a solid tumor to collapse so that VDAs (Vascular disrupting agents) can deprive the tumor of blood and oxygen the tumors need to survive, resulting in tumor ischemia and necrosis. Small molecule vascular disrupting agents including flavonoids, tubulin-binding agents are extremely important for both maintaining tumor growth and controlling the tumor environment.

Angiogenesis

Aurora Kinase CDK Chk ROCK Antimetabolites APC Wee1 MPS1 Rho Myc DYRK BMI-1 eIF LIM kinase PFKFB RUNX Nur77 FOXM1 Choline kinase Haspin Kinase Mad2 p21 Cyclin CDK4/6 Cell Cycle Arrest
  • All (3)
  • New VDA Products
Cat.No. Product Name Information Product Use Citations Product Validations
S1786 Verteporfin Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Nat Commun, 2025, 16(1):4124
Adv Sci (Weinh), 2025, 12(44):e11726
Cell Death Differ, 2025, 10.1038/s41418-025-01446-2
Verified customer review of Verteporfin
S1537 Vadimezan (DMXAA) Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. It is also a STING agonist with potential antineoplastic activity, potently inducing IFN-β but relatively low TNF-α expression in vitro. This compound has antiviral activity. Phase 3.
Cell Chem Biol, 2025, 32(2):280-290.e14
Commun Biol, 2025, 8(1):1470
Front Pharmacol, 2025, 16:1528459
Verified customer review of Vadimezan (DMXAA)
S1176 Plinabulin Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
J Med Chem, 2022, 65(13):9159-9173
ACS Omega, 2022, 7(25):21465-21472
J Biol Chem, 2019, 294(20):8161-8170

Signaling Pathway Map